Literature DB >> 33418946

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications.

Numa Piot1, F Gisou van der Goot1, Oksana A Sergeeva1.   

Abstract

Over the last few decades, proteins and peptides have become increasingly more common as FDA-approved drugs, despite their inefficient delivery due to their inability to cross the plasma membrane. In this context, bacterial two-component systems, termed AB toxins, use various protein-based membrane translocation mechanisms to deliver toxins into cells, and these mechanisms could provide new insights into the development of bio-based drug delivery systems. These toxins have great potential as therapies both because of their intrinsic properties as well as the modular characteristics of both subunits, which make them highly amenable to conjugation with various drug classes. This review focuses on the therapeutical approaches involving the internalization mechanisms of three representative AB toxins: botulinum toxin type A, anthrax toxin, and cholera toxin. We showcase several specific examples of the use of these toxins to develop new therapeutic strategies for numerous diseases and explain what makes these toxins promising tools in the development of drugs and drug delivery systems.

Entities:  

Keywords:  anthrax toxin; botulinum toxin; cholera toxin; drug delivery; endocytosis; membrane translocation; therapeutic applications

Mesh:

Substances:

Year:  2021        PMID: 33418946      PMCID: PMC7825107          DOI: 10.3390/toxins13010036

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  107 in total

1.  Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice.

Authors:  Shihui Liu; Sharmina Miller-Randolph; Devorah Crown; Mahtab Moayeri; Inka Sastalla; Shu Okugawa; Stephen H Leppla
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

2.  An initial assessment of the systemic pharmacokinetics of botulinum toxin.

Authors:  Easwaran Ravichandran; Yujing Gong; Fetweh H Al Saleem; Denise M Ancharski; Suresh G Joshi; Lance L Simpson
Journal:  J Pharmacol Exp Ther       Date:  2006-06-16       Impact factor: 4.030

3.  Imaging specific cell-surface proteolytic activity in single living cells.

Authors:  John P Hobson; Shihui Liu; Birgitte Rønø; Stephen H Leppla; Thomas H Bugge
Journal:  Nat Methods       Date:  2006-04       Impact factor: 28.547

4.  Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin.

Authors:  Andreas Rummel; Stefan Mahrhold; Hans Bigalke; Thomas Binz
Journal:  FEBS J       Date:  2011-06-22       Impact factor: 5.542

Review 5.  The future of peptide-based drugs.

Authors:  David J Craik; David P Fairlie; Spiros Liras; David Price
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

6.  Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Authors:  N S Duesbery; C P Webb; S H Leppla; V M Gordon; K R Klimpel; T D Copeland; N G Ahn; M K Oskarsson; K Fukasawa; K D Paull; G F Vande Woude
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

7.  Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.

Authors:  Yien Che Tsai; Rhyan Maditz; Chueh-ling Kuo; Paul S Fishman; Charles B Shoemaker; George A Oyler; Allan M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

8.  Potent antitumor activity of a urokinase-activated engineered anthrax toxin.

Authors:  Shihui Liu; Hannah Aaronson; David J Mitola; Stephen H Leppla; Thomas H Bugge
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

9.  Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.

Authors:  Laura Restani; Francesco Giribaldi; Maria Manich; Kinga Bercsenyi; Guillermo Menendez; Ornella Rossetto; Matteo Caleo; Giampietro Schiavo
Journal:  PLoS Pathog       Date:  2012-12-27       Impact factor: 6.823

Review 10.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.